Insights

Innovation Focus Kallyope is at the forefront of developing oral therapies for metabolic, neurological, and gastrointestinal diseases, offering potential collaborations or licensing opportunities for companies focused on complementary treatment areas or advanced drug delivery technologies.

Recent Public Offering As a newly public company seeking to capitalize on investor interest in obesity treatments, Kallyope may be open to strategic partnerships, joint ventures, or technology licensing deals to accelerate development and expand market reach.

Technological Capabilities Leveraging sophisticated techniques including GPCR targeting and gut-brain axis research, Kallyope represents a compelling partner for firms specializing in bioinformatics, molecular diagnostics, or advanced analytics aimed at personalized medicine.

Funding and Grants With substantial financial backing including an $8.2 million grant from the Bill & Melinda Gates Foundation, Kallyope is focused on global health challenges, providing opportunities for collaborations in public health initiatives or multinational research projects.

Leadership Expansion Recent high-level hires and board leadership appointments suggest Kallyope is expanding its scientific and strategic capabilities, making it receptive to vendor relationships, scientific collaborations, and innovative research partnerships.

Kallyope Tech Stack

Kallyope uses 8 technology products and services including Open Graph, git, Microsoft Excel, and more. Explore Kallyope's tech stack below.

  • Open Graph
    Content Management System
  • git
    Development
  • Microsoft Excel
    Editors
  • Python
    Programming Languages
  • Java
    Programming Languages
  • Paylocity
    Recruitment Marketing
  • HSTS
    Security
  • Google Tag Manager
    Tag Management

Media & News

Kallyope's Email Address Formats

Kallyope uses at least 1 format(s):
Kallyope Email FormatsExamplePercentage
First@kallyope.comJohn@kallyope.com
33%
First.Last@kallyope.comJohn.Doe@kallyope.com
17%
First@kallyope.comJohn@kallyope.com
33%
First.Last@kallyope.comJohn.Doe@kallyope.com
17%

Frequently Asked Questions

What is Kallyope's phone number?

Minus sign iconPlus sign icon
You can contact Kallyope's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Kallyope's official website and social media links?

Minus sign iconPlus sign icon
Kallyope's official website is kallyope.com and has social profiles on LinkedInCrunchbase.

What is Kallyope's SIC code NAICS code?

Minus sign iconPlus sign icon
Kallyope's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Kallyope have currently?

Minus sign iconPlus sign icon
As of December 2025, Kallyope has approximately 69 employees across 3 continents, including North AmericaAsiaSouth America. Key team members include Chief Scientific Officer: S. P.Chief Financial Officer: P. E. F.Chief Medical Officer: B. L.. Explore Kallyope's employee directory with LeadIQ.

What industry does Kallyope belong to?

Minus sign iconPlus sign icon
Kallyope operates in the Biotechnology Research industry.

What technology does Kallyope use?

Minus sign iconPlus sign icon
Kallyope's tech stack includes Open GraphgitMicrosoft ExcelPythonJavaPaylocityHSTSGoogle Tag Manager.

What is Kallyope's email format?

Minus sign iconPlus sign icon
Kallyope's email format typically follows the pattern of First@kallyope.com. Find more Kallyope email formats with LeadIQ.

How much funding has Kallyope raised to date?

Minus sign iconPlus sign icon
As of December 2025, Kallyope has raised $1.2B in funding. The last funding round occurred on Feb 15, 2022 for $236M.

When was Kallyope founded?

Minus sign iconPlus sign icon
Kallyope was founded in 2015.

Kallyope

Biotechnology ResearchNew York, United States51-200 Employees

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. 

Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease.

Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development.

Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
51-200

Section iconFunding & Financials

  • $1.2B

    Kallyope has raised a total of $1.2B of funding over 8 rounds. Their latest funding round was raised on Feb 15, 2022 in the amount of $236Mas a Series D.

  • $25M$50M

    Kallyope's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $1.2B

    Kallyope has raised a total of $1.2B of funding over 8 rounds. Their latest funding round was raised on Feb 15, 2022 in the amount of $236Mas a Series D.

  • $25M$50M

    Kallyope's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.